Home » Newsletters » BioWorld Science

BioWorld Science

June 24, 1997

View Archived Issues

MS&D describes potent and selective 5-HT1Dalpha receptor agonists

Agents for depression and related disorders from American Home Products

Merck & Co.'s new immunosuppressants

Antibacterial agents from Ortho

Schering-Plough isolates potential lead for new schizophrenia drugs from Chinese plant

Lilly licenses Prozac patent rights from Interneuron for PMS treatment

PBR ligand-melphalan conjugate with promise for brain tumors

Recombinant PAF-AH progresses to phase II for ARDS

SmithKline Beecham introduces ReQuip in Germany

Three-drug therapy shown effective against AIDS

Penclomedine: phase I results in patients with solid tumors

Antiasthmatic activity of NPC-17731 in primate model

Ranitidine for infectious mononucleosis

Gemcitabine vs. cisplatin + etoposide for stage III-IV NSCLC

Safety and pharmacokinetics of JTP-4819 in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.